Ivana Šestak

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Jack Cuzick, Ivana Šestak, Michael Baum et al. · The Lancet Oncology · 2010 · 1.7K citations

Medicine, Oncology, Pharmacology +15

Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Mitch Dowsett, Ivana Šestak, Elena López‐Knowles et al. · Journal of Clinical Oncology · 2013 · 636 citations · Full text

Medicine, Oncology, Breast Oncology +16

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

Jack Cuzick, Ivana Šestak, John Forbes et al. · The Lancet · 2013 · 585 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

Jack Cuzick, Ivana Šestak, Sarah E. Pinder et al. · The Lancet Oncology · 2010 · 569 citations · Full text

Medicine, Oncology, Radiation Oncology +11

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Brett Wallden, James J. Storhoff, Torsten O. Nielsen et al. · BMC Medical Genomics · 2015 · 560 citations · Full text

Medicine, Bioinformatics, Oncology +17